As Pfizer shares surge, should I buy the stock now?

This Fool explains why he thinks Pfizer shares remain incredibly attractive at current levels, despite their recent performance.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pfizer (NYSE: PFE) shares have surged in value over the past four weeks. Since the first week of October, the stock has added 15%. By comparison, America’s leading stock market index, the S&P 500, has returned just 8% over the same time frame.

Over the past year, Pfizer shares have produced a total return of 41%, outpacing the S&P 500’s total return of around 26%. 

Pfizer shares surge

Investor sentiment towards the pharmaceuticals group has been buoyed by its coronavirus treatments. Not only does the company jointly produce one of the world’s leading vaccinations for the virus, but it also recently published strong clinical data for its coronavirus antiviral treatment, Paxlovid

In non-hospitalised coronavirus patients, this treatment substantially reduces the risk of hospitalisation by 89%. Some doctors and analysts have described it as a game-changing development in the world’s battle against this disease. 

That is why shares in the company have performed so well recently. However, this is unlikely to be a substantial long-term revenue generator for the group.

Almost every single large pharmaceutical company in the world is working on different coronavirus treatments, so the competition is fierce. Pfizer’s offer may be one of the first out of the gate, but it certainly will not be the last. 

But there is far more to the company than just its coronavirus drugs. 

Sector giant

Pfizer is one of the world’s largest pharmaceutical corporations with a broad portfolio of products and treatments. The company recently said it is projecting total revenues of $81bn for the current financial year. Of this, $36bn will account for sales of its coronavirus vaccine. 

Aside from this blockbuster treatment, the company has seven other flagship treatments in development and on the market. These include the blood thinner Eliquis and cardiovascular drugs Vyndaqel/Vyndamax. Sales for both of these drugs jumped by a double-digit percentage in the third quarter. 

On top of these, the group has a further 94 drugs under development. Of these, 29 are in stage-three testing (the final step before submitting them to regulators for approval).

Of course, there is no guarantee these products will ever make it to market. If they do not, the company could struggle to replace revenues from its coronavirus vaccine over the next few years. This is probably the biggest challenge the group faces right now.

As I noted above, competition in the coronavirus treatment space is fierce, and while Pfizer may be benefitting from a revenue boost today, it is not clear how much longer that will last. Management is already projecting vaccine revenue will fall to $29bn in 2022. 

Still, despite this risk, I think Pfizer shares look attractive considering the company’s valuation, treatment pipeline, and dividend potential. The stock is selling at a forward price-to-earnings (P/E) multiple of 11.6 and offers a 3.2% dividend yield. 

As the firm continues to build on its successes over the past year, I would buy the stock for my portfolio today. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Photo of a man going through financial problems
Investing Articles

I asked ChatGPT to name the FTSE 250 share it would buy in a heartbeat – and it went mad!

Harvey Jones wondered whether artificial intelligence was up to the job of finding him a brilliant FTSE 250 share to…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

Is the BP share price primed for lift off?

As an activist investor takes a substantial holding in BP, Andrew Mackie assesses what it will take to energise the…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

No savings? I’m using the 5-step Warren Buffett method as I aim to get rich

Christopher Ruane outlines a handful of investment techniques he uses, inspired by the incredible stock market record of Warren Buffett.

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With a spare £3,000, here’s how a new investor could start buying shares

Our writer explains how someone with a few thousand pounds and no prior stock market experience could start buying shares…

Read more »

UK money in a Jar on a background
Investing Articles

£10,000 invested in Greggs shares in 2020 has made this much passive income…

Greggs shares have struggled lately due to economic weakness and rising costs. Are they still worth considering for an ISA…

Read more »

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

Don’t look now, but the FTSE 100’s beating the S&P 500 in 2025…

So far this year, UK stocks have been doing better than their US counterparts. So is the FTSE 100 the…

Read more »

Investing Articles

How much would someone need in UK shares to earn £5,000 in passive income each month?

Thousands of Stocks and Shares ISA investors have built up more than a million pounds and can sit back and…

Read more »

Investing Articles

£10,000 invested in Tesla stock 1 month ago is now worth…

Tesla stock is remarkably volatile for a mega-cap company. While this presents some opportunities for investors, it’s also inherently risky.

Read more »